These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15788735)

  • 1. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.
    McLemore MR; Aouizerat B
    Biol Res Nurs; 2005 Apr; 6(4):262-7. PubMed ID: 15788735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer screening: a look at the evidence.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and detection of ovarian cancer.
    Breedlove G; Busenhart C
    J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current clinical use of biomarkers for epithelial ovarian cancer.
    Moore RG; Maclaughlan S
    Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
    Boivin M; Lane D; Piché A; Rancourt C
    Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker discovery in epithelial ovarian cancer by genomic approaches.
    Mok SC; Elias KM; Wong KK; Ho K; Bonome T; Birrer MJ
    Adv Cancer Res; 2007; 96():1-22. PubMed ID: 17161674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor marker in ovarian cancer].
    Komai K; Nishida T
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H; Duranyildiz D; Tas F; Yasasever V
    Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
    Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
    J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
    Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
    Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
    Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
    Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
    Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer.
    Chen K; Gentry-Maharaj A; Burnell M; Steentoft C; Marcos-Silva L; Mandel U; Jacobs I; Dawnay A; Menon U; Blixt O
    J Proteome Res; 2013 Mar; 12(3):1408-18. PubMed ID: 23360124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.